Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRA | P18433 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.95 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | BLM | P54132 | 2/20 | 0.60 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | MPO | P05164 | 1/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | HTR1A | P08908 | 1/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | HTR2A | P28223 | 1/20 | 0.56 |
| ▸ | HTR2C | P28335 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3519524 | 1.00 | PTPRA (1.00) | PTPRACYP2C19KMT2AKDM4ELMNA | |
| SCHEMBL30789181 | 1.00 | PTPRA (1.00) | PTPRACYP2C19KMT2AKDM4ELMNA | |
| SCHEMBL30381729 | 1.00 | PTPRA (1.00) | PTPRACYP2C19KMT2AKDM4ELMNA | |
| SCHEMBL145392 | 1.00 | PTPRA (1.00) | PTPRACYP2C19KMT2AKDM4ELMNA | |
| SCHEMBL1580111 | 0.90 | PTPRA (0.82) | PTPRACYP2C19KMT2AKDM4ELMNA | |
| SCHEMBL1580112 | 0.90 | PTPRA (0.82) | PTPRACYP2C19KMT2AKDM4ELMNA | |
| SCHEMBL22288108 | 0.86 | PTPRA (0.75) | PTPRACYP2C19KMT2AKDM4ELMNA | |
| SCHEMBL20931031 | 0.86 | PTPRA (0.75) | PTPRACYP2C19KMT2AKDM4ELMNA | |
| SCHEMBL22288107 | 0.86 | PTPRA (0.75) | PTPRACYP2C19KMT2AKDM4ELMNA | |
| SCHEMBL7380735 | 0.85 | PTPRA (0.73) | PTPRACYP2C19KMT2AKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11813280-B2 | Reducing beta-catenin and IDO expression to potentiate immunotherapy | DICERNA PHARMACEUTICALS, INC. (US) | 2023-11-14 | — | — | US | claimed |
| US-20200338110-A1 | REDUCING BETA-CATENIN AND IDO EXPRESSION TO POTENTIATE IMMUNOTHERAPY | DICERNA PHARMACEUTICALS, INC. | 2020-10-29 | — | — | US | claimed |
| EP-3697423-A2 | REDUCING BETA-CATENIN AND IDO EXPRESSION TO POTENTIATE IMMUNOTHERAPY | Dicerna Pharmaceuticals, Inc. (US) | 2020-08-26 | — | — | EP | claimed |
| CN-111587116-A | Decreasing beta-catenin and IDO expression to boost immunotherapy | 迪克纳制药公司 | 2020-08-25 | — | — | CN | claimed |
| WO-2019136157-A2 | REDUCING BETA-CATENIN AND IDO EXPRESSION TO POTENTIATE IMMUNOTHERAPY | DICERNA PHARMACEUTICALS, INC. (US) | 2019-07-11 | — | — | WO | claimed |
| US-20150196533-A1 | METHOD FOR CONCURRENT TREATMENT OF PAIN AND DEPRESSION | THE GENERAL HOSPITAL CORPORATION | 2015-07-16 | — | — | US | claimed |
| WO-2014008118-A2 | METHOD FOR CONCURRENT TREATMENT OF PAIN AND DEPRESSION | THE GENERAL HOSPITAL CORPORATION (US) | 2014-01-09 | — | — | WO | claimed |
| US-20090191283-A1 | TREATMENT OF HEADACHES, NECK PAIN, JOINT PAIN AND INFLAMMATORY-TYPE PAIN | EPICENTRX, INC. | 2009-07-30 | — | — | US | claimed |
| WO-2008124184-A1 | TREATMENT OF HEADACHES, NECK PAIN, JOINT PAIN AND INFLAMMATORY-TYPE PAIN | XVASIVE INC. (US) | 2008-10-16 | — | — | WO | claimed |
| EP-1501918-A4 | ANTIGEN-PRESENTING CELL POPULATIONS AND THEIR USE AS REAGENTS FOR ENHANCING OR REDUCING IMMUNE TOLERANCE | MED COLLEGE GEORGIA RES INST (US) | 2006-03-29 | — | — | EP | claimed |
| US-20050186289-A1 | Regulation of T cell-mediated immunity by D isomers of inhibitors of indoleamine-2,3-dioxygenase | MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE, INC. (US) | 2005-08-25 | — | — | US | claimed |
| EP-1501918-A1 | ANTIGEN-PRESENTING CELL POPULATIONS AND THEIR USE AS REAGENTS FOR ENHANCING OR REDUCING IMMUNE TOLERANCE | Medical College Of Georgia Research Institute, Inc. (US) | 2005-02-02 | — | — | EP | claimed |
| US-20040234623-A1 | Anticancer agents; infection; immunosuppressants | MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE, INC. (US) | 2004-11-25 | — | — | US | claimed |
| WO-2003087347-A1 | ANTIGEN-PRESENTING CELL POPULATIONS AND THEIR USE AS REAGENTS FOR ENHANCING OR REDUCING IMMUNE TOLERANCE | MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE, INC. (US) | 2003-10-23 | — | — | WO | claimed |
| US-20030194803-A1 | Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-10-16 | — | — | US | claimed |
| US-11813280-B2 | Reducing beta-catenin and IDO expression to potentiate immunotherapy | DICERNA PHARMACEUTICALS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230057350-A1 | A CONJUGATE OF AN AMANITA TOXIN WITH BRANCHED LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-02-23 | — | — | US | disclosed |
| EP-0001295-B1 | SOMATOSTATIN-LIKE CYCLOPEPTIDES, A PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR THERAPEUTICAL APPLICATION | CIBA-GEIGY AG (CH) | 1982-03-17 | — | — | EP | disclosed |
| US-4238481-A | HYPOGLYCEMIC AGENT; HYPERGLYCEMIC AGENT; ANIMAL GROWTH REGULATOR | CIBA-GEIGY CORPORATION (US) | 1980-12-09 | — | — | US | disclosed |
| EP-0001295-A2 | Somatostatin-like cyclopeptides, a process for their preparation, pharmaceutical compositions containing them, and their therapeutical application | CIBA-GEIGY AG (CH) | 1979-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11813280-B2 | Reducing beta-catenin and IDO expression to potentiate immunotherapy | IDO1, CTNNB1, IDO2 | PTPRA 2640/4885CYP2C19 4761/4885KMT2A 487/4885 |
| US-20230057350-A1 | A CONJUGATE OF AN AMANITA TOXIN WITH BRANCHED LINKERS | BTN3A1, ANTXR2, CLTA | PTPRA 845/4885CYP2C19 4855/4885KMT2A 1268/4885 |
| US-20200338110-A1 | REDUCING BETA-CATENIN AND IDO EXPRESSION TO POTENTIATE IMMUNOTHERAPY | IDO1, CTNNB1, IDO2 | PTPRA 2640/4885CYP2C19 4761/4885KMT2A 487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.